← All market papers

Interventional Psychiatry Market Report: TMS vs. Spravato

Medicare TMS (90867–90869) and Spravato (Part B G2082/G2083, Part D, Medicaid) · 2022–2024

Side-by-side adoption of the two leading treatment-resistant depression modalities from completed CMS imports: providers, services, payments, states and multi-modality clinicians, with programs never summed.

Built for Interventional psychiatry clinics, neurostimulation and esketamine field teams, and behavioral-health M&A advisors.

See our sources

What's inside the full paper

  • Executive summary
  • TMS: Medicare providers, services and payments by year
  • TMS by code
  • Spravato by program and year
  • State adoption comparison (2024 TMS vs. 2024 Spravato Part D)
  • TMS clinician specialties (2024)
  • Methods and limits

Free preview

Executive summary

Prepared 2026-11-20 from completed CMS imports. In 2024, 391 Medicare clinicians billed TMS (90867–90869); 1,338 distinct NPIs appear in 2024 Spravato records across Medicare Part B, Part D and Medicaid.

TMS Medicare payments moved from $22,166,329 (2022) to $35,443,306 (2024). 95 clinicians appear in both the latest TMS and Spravato cohorts — the multi-modality interventional practices most likely to expand.

Programs are shown side by side and never summed: Part B pays the in-office administration and monitoring, Part D pays the drug, and Medicaid uses different reporting.

TMS: Medicare providers, services and payments by year

Payments are services × CMS average Medicare payment per rendering NPI, code and place of service.

YearCliniciansServicesMedicare paid
2022310157,762$22,166,329
2023319168,342$23,393,041
2024391239,355$35,443,306

TMS by code

90867 initial mapping, 90868 subsequent delivery, 90869 re-mapping.

YearCodeCliniciansServicesMedicare paid
2022908671593,684$739,896
202290868309152,069$21,015,926
202290869612,009$410,507

6 more rows in the full paper

Statistical results are review leads, not findings of fraud. See our sources.